<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01495481</url>
  </required_header>
  <id_info>
    <org_study_id>PRO11070129</org_study_id>
    <secondary_id>PRE-11-010</secondary_id>
    <nct_id>NCT01495481</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine and Adenosine: Therapeutic Use for SVT</brief_title>
  <official_title>Dexmedetomidine Versus Adenosine: Electrophysiologic Effects and Therapeutic Use for Terminating Supraventricular Tachycardia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of dexmedetomidine in the
      acute termination of Supraventricular Tachycardia (SVT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In 2006 the investigator found that dexmedetomidine, an alpha-2 adrenergic agonist with
      primarily sedative properties, possesses additional anti-arrhythmic properties. So far the
      investigator has found that dexmedetomidine has the ability to prevent or terminate
      arrhythmias like atrial ectopic tachycardia (85% success) and junctional ectopic tachycardia
      (75% success). The most dramatic effect however was observed in the acute termination of
      reentrant SVT with a success rate of &gt; 96%. More importantly we found that dexmedetomidine
      terminates SVT without causing any sinus pause or asystole (frequently seen with adenosine)
      and thus avoiding the feeling of &quot;impending doom&quot;. In this study adenosine is being compared
      head to head with dexmedetomidine in a cross over study, for both safety and efficacy when
      given for the termination of SVT in the electrophysiology (EP) lab. Additional EP parameters
      will be measured to elucidate the exact site of dexmedetomidine's mechanism of action.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Termination of SVT</measure>
    <time_frame>Within 3 minutes</time_frame>
    <description>Number of participants with SVT Termination within 3 minutes of medication administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Sinus Pause &gt;2.5 Sec After Termination of SVT</measure>
    <time_frame>1 minute</time_frame>
    <description>Evaluation of the number of participants with sinus pause &gt; 2.5 sec, after dexmedetomidine vs. adenosine induced SVT termination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Tachyarrhythmias After Medication Administration</measure>
    <time_frame>10 minutes</time_frame>
    <description>Number of participants with tachyarrhythmias, including Ventricular (Ventricular Tachycardia &amp; Fibrillation)and supraventricular (Atrial Flutter &amp; Fibrillation) after dexmedetomidine vs. adenosine administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hypotension by Non-invasive Cuff in First 10 Minutes After Medication Administration</measure>
    <time_frame>10 minutes</time_frame>
    <description>Blood pressure changes after dexmedetomidine vs. adenosine. Blood pressure measured by non-invasive cuff prior to medication administration, and then at 1 min, 3 min, 5 min after medication administration. Number of participants with a significant drop in blood pressure (mmHg) compared to baseline would be counted for hypotension.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Supraventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Adenosine and Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive adenosine and then dexmedetomidine for the termination of SVT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine 2 mcg/kg, Intravenous push</description>
    <arm_group_label>Adenosine and Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine</intervention_name>
    <description>Stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful</description>
    <arm_group_label>Adenosine and Dexmedetomidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between the age of 5 - 30 years old, who are scheduled for cardiac
             electrophysiology study for evaluation of reentrant SVT

        Exclusion Criteria:

          -  Severe Heart Failure

          -  Presence of of any other antiarrhythmic medication within 24 hours of enrollment

          -  Third degree heart block

          -  Sick Sinus Syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaurav Arora, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chrysostomou C, Beerman L, Shiderly D, Berry D, Morell VO, Munoz R. Dexmedetomidine: a novel drug for the treatment of atrial and junctional tachyarrhythmias during the perioperative period for congenital cardiac surgery: a preliminary study. Anesth Analg. 2008 Nov;107(5):1514-22. doi: 10.1213/ane.0b013e318186499c.</citation>
    <PMID>18931208</PMID>
  </reference>
  <reference>
    <citation>Chrysostomou C, Sanchez-de-Toledo J, Wearden P, Jooste EH, Lichtenstein SE, Callahan PM, Suresh T, O'Malley E, Shiderly D, Haney J, Yoshida M, Orr R, Munoz R, Morell VO. Perioperative use of dexmedetomidine is associated with decreased incidence of ventricular and supraventricular tachyarrhythmias after congenital cardiac operations. Ann Thorac Surg. 2011 Sep;92(3):964-72; discussion 972. doi: 10.1016/j.athoracsur.2011.04.099.</citation>
    <PMID>21871284</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2011</study_first_posted>
  <results_first_submitted>February 18, 2016</results_first_submitted>
  <results_first_submitted_qc>February 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 28, 2017</results_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Gaurav Arora</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Supraventricular Tachycardia</keyword>
  <keyword>SVT</keyword>
  <keyword>Reentrant Tachycardia</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Adenosine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Supraventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All 22 patients recruited received both adenosine and dexmedetomidine. Adenosine was administered first ,and then SVT was reinduced. Once SVT was reinduced, dexmedetomidine was administered.
The washout period was not constant because it was dependent upon the reinduction of SVT, but it was generally less than 10 min.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adenosine and Dexmedetomidine</title>
          <description>Patients will receive adenosine for termination of SVT, and then dexmedetomidine for the termination of supraventricular tachycardia (SVT) and comparison will be made for efficacy and safety.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Adenosine</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22">Patients first received adenosine and then dexmedetomidine.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Dexmedetomidine</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adenosine and Dexmedetomidine</title>
          <description>Patients will receive both adenosine and dexmedetomidine for the termination of SVT.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Termination of SVT</title>
        <description>Number of participants with SVT Termination within 3 minutes of medication administration</description>
        <time_frame>Within 3 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Patients will receive dexmedetomidine for the termination of SVT
Dexmedetomidine: Dexmedetomidine 1 mcg/kg, Intravenous push</description>
          </group>
          <group group_id="O2">
            <title>Adenosine</title>
            <description>Patients will receive Adenosine for the termination of SVT
Adenosine: stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful</description>
          </group>
        </group_list>
        <measure>
          <title>Termination of SVT</title>
          <description>Number of participants with SVT Termination within 3 minutes of medication administration</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Sinus Pause &gt;2.5 Sec After Termination of SVT</title>
        <description>Evaluation of the number of participants with sinus pause &gt; 2.5 sec, after dexmedetomidine vs. adenosine induced SVT termination</description>
        <time_frame>1 minute</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Patients will receive dexmedetomidine for the termination of supraventricular tachycardia (SVT)
Dexmedetomidine: Dexmedetomidine 2 mcg/kg, Intravenous push</description>
          </group>
          <group group_id="O2">
            <title>Adenosine</title>
            <description>Patients will receive Adenosine for the termination of SVT
Adenosine: stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sinus Pause &gt;2.5 Sec After Termination of SVT</title>
          <description>Evaluation of the number of participants with sinus pause &gt; 2.5 sec, after dexmedetomidine vs. adenosine induced SVT termination</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Tachyarrhythmias After Medication Administration</title>
        <description>Number of participants with tachyarrhythmias, including Ventricular (Ventricular Tachycardia &amp; Fibrillation)and supraventricular (Atrial Flutter &amp; Fibrillation) after dexmedetomidine vs. adenosine administration</description>
        <time_frame>10 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Patients will receive dexmedetomidine for the termination of supraventricular tachycardia (SVT)
Dexmedetomidine: Dexmedetomidine 1 mcg/kg, Intravenous push</description>
          </group>
          <group group_id="O2">
            <title>Adenosine</title>
            <description>Patients will receive Adenosine for the termination of SVT
Adenosine: stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tachyarrhythmias After Medication Administration</title>
          <description>Number of participants with tachyarrhythmias, including Ventricular (Ventricular Tachycardia &amp; Fibrillation)and supraventricular (Atrial Flutter &amp; Fibrillation) after dexmedetomidine vs. adenosine administration</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hypotension by Non-invasive Cuff in First 10 Minutes After Medication Administration</title>
        <description>Blood pressure changes after dexmedetomidine vs. adenosine. Blood pressure measured by non-invasive cuff prior to medication administration, and then at 1 min, 3 min, 5 min after medication administration. Number of participants with a significant drop in blood pressure (mmHg) compared to baseline would be counted for hypotension.</description>
        <time_frame>10 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Patients will receive dexmedetomidine for the termination of supraventricular tachycardia (SVT)
Dexmedetomidine: Dexmedetomidine 2 mcg/kg, Intravenous push</description>
          </group>
          <group group_id="O2">
            <title>Adenosine</title>
            <description>Patients will receive Adenosine for the termination of SVT
Adenosine: stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypotension by Non-invasive Cuff in First 10 Minutes After Medication Administration</title>
          <description>Blood pressure changes after dexmedetomidine vs. adenosine. Blood pressure measured by non-invasive cuff prior to medication administration, and then at 1 min, 3 min, 5 min after medication administration. Number of participants with a significant drop in blood pressure (mmHg) compared to baseline would be counted for hypotension.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexmedetomidine</title>
          <description>Patients will receive dexmedetomidine for the termination of SVT
Dexmedetomidine: Dexmedetomidine 1 mcg/kg, Intravenous push</description>
        </group>
        <group group_id="E2">
          <title>Adenosine</title>
          <description>Patients will receive Adenosine for the termination of SVT
Adenosine: stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gaurav Arora</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-692-6054</phone>
      <email>gaurav.arora@chp.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

